This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in
hemodialysis participants. This study will involve multiple doses of LY2928057 given during a
6 week period either after a participant discontinues or reduces treatment to stimulate red
blood cells. This study will last up to 26 weeks for each participant.